INT73128

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 1997
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 9
Disease Relevance 4.42
Pain Relevance 4.27

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pde5a) signal transduction (Pde5a)
Anatomy Link Frequency
paw 1
Pde5a (Mus musculus)
Pain Link Frequency Relevance Heat
Antinociceptive 5 99.98 Very High Very High Very High
long-term potentiation 185 99.82 Very High Very High Very High
Serotonin 22 99.22 Very High Very High Very High
diabetic neuropathy 8 99.00 Very High Very High Very High
opioid receptor 4 98.68 Very High Very High Very High
agonist 18 98.04 Very High Very High Very High
diclofenac 4 96.88 Very High Very High Very High
Delta opioid receptors 1 95.92 Very High Very High Very High
Neuronal nitric oxide synthase 2 95.44 Very High Very High Very High
tolerance 5 95.04 Very High Very High Very High
Disease Link Frequency Relevance Heat
Nociception 7 99.44 Very High Very High Very High
Cognitive Disorder 284 99.16 Very High Very High Very High
Diabetic Neuropathy 8 99.00 Very High Very High Very High
Diabetes Mellitus 27 97.92 Very High Very High Very High
Peripheral Neuropathy 2 96.24 Very High Very High Very High
Hyperalgesia 10 95.00 High High
Hyperaesthesia 2 93.96 High High
Pain 6 83.76 Quite High
Shock 16 76.72 Quite High
Anaerobic Bacterial Infections 3 52.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The present study was aimed at evaluating the role of PDE-5 inhibitor on nociception in streptozotocin-induced diabetes in animal models of nociception (writhing assay in mice and paw hyperalgesia test in rats).
Regulation (role) of PDE-5 in paw associated with nociception, hyperalgesia and diabetes mellitus
1) Confidence 0.37 Published 2004 Journal Pharmacology Section Abstract Doc Link 15452368 Disease Relevance 1.53 Pain Relevance 0.76
Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy.
Regulation (effect) of PDE-5 associated with diabetic neuropathy
2) Confidence 0.37 Published 2004 Journal Pharmacology Section Title Doc Link 15452368 Disease Relevance 1.70 Pain Relevance 0.75
Most research regarding the cognition-enhancing effects of PDE5-Is so far has focused on preclinical animal models; there are only two papers in which the effects of the PDE5-I sildenafil on human cognition were investigated.
Regulation (effects) of PDE5-I associated with cognitive disorder
3) Confidence 0.20 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.55 Pain Relevance 0
In general, both presynaptic and postsynaptic mechanisms are related to LTP and can involve the second messengers cAMP and cGMP.
Regulation (involve) of cGMP associated with long-term potentiation
4) Confidence 0.17 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.05 Pain Relevance 0.79
Little is known about the PDE isoforms responsible for cGMP hydrolysis in individual cell types, and there may be mixtures at work.
Regulation (responsible) of cGMP
5) Confidence 0.14 Published 2008 Journal The European Journal of Neuroscience Section Body Doc Link PMC2610389 Disease Relevance 0 Pain Relevance 0.08
In the pond snail, serotonin transmission was markedly (up to 80%) dependent on endogenous NO acting postsynaptically through cGMP and PKG, perhaps bringing about phosphorylation of the serotonin receptor (Straub et al., 2007).
Regulation (dependent) of cGMP associated with serotonin
6) Confidence 0.14 Published 2008 Journal The European Journal of Neuroscience Section Body Doc Link PMC2610389 Disease Relevance 0 Pain Relevance 0.20
The antinociceptive effect of the PDE-5 inhibitor, sildenafil, alone or in combination with cyclooxygenase inhibitor diclofenac and nimesulide, was assessed in the different animal models of peripheral nociception.
Regulation (effect) of PDE-5 associated with nociception, diclofenac and antinociceptive
7) Confidence 0.11 Published 2003 Journal Pharmacology Section Abstract Doc Link 14624058 Disease Relevance 0.27 Pain Relevance 0.30
It seems likely that additional modulators are involved in regulating and mediating the timed effect of the second messengers cGMP and cAMP on memory processes.


Regulation (regulating) of cGMP
8) Confidence 0.10 Published 2008 Journal Psychopharmacology (Berl) Section Body Doc Link PMC2704616 Disease Relevance 0.33 Pain Relevance 0.27
Since activation of NO increases the production of cGMP, the present results demonstrating alterations of cGMP levels by mu-, kappa- and delta-opioid receptor agonists are consistent with the behavioral results with NOS inhibitors on tolerance to mu-, kappa- and delta-opioid receptor agonists.
Regulation (alterations) of cGMP associated with tolerance, agonist and opioid receptor
9) Confidence 0.04 Published 1997 Journal Peptides Section Abstract Doc Link 9437726 Disease Relevance 0 Pain Relevance 1.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox